Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Gemcitabine, Paclitaxel, and Avastin in Metastatic Breast Cancer
NCT00618826Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Nov 2006
- Primary completion
- Feb 2014
- Modality
- Monoclonal Antibodies, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Paclitaxel Micelles for Injection, gemcitabine and bevacizumab in breast cancer, sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Progression-free Survival. Started Nov 2006; status: completed.
02
Drugs
Paclitaxel Micelles for Injectiongemcitabinebevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00618826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00618826.